LUTONIX® 035 DCB Mechanism of Action[1]

Paclitaxel → Inhibits Cell Division + Inhibits Cell Growth = **Inhibits Intimal Hyperplasia**

How It Works

LUTONIX® 035 DCB



Treated Vessel



After pre-dilatation, LUTONIX® 035 DCB is delivered to the target lesion and inflated for a minimum of 2 minutes. During this time, a therapeutic dose of paclitaxel is transferred to the vessel's endoluminal surface. The balloon is then deflated and removed.

1. After pre-dilating the stenotic lesion in the dysfunctional fistula, the DCB should be centered across the entire treated area
2. Two minute minimum inflation transfers therapeutic dose of the drug to the vessel wall
3. Paclitaxel inhibits restenosis in the vessel by inhibiting smooth muscle cell proliferation and migration, preventing neointimal hyperplasia formation
4. LUTONIX® 035 DCB extends complication-free survival by lengthening the time to restenosis and improving fistula function

LUTONIX® 035
Drug Coated Balloon PTA Catheter

BARD

Advancing Lives and the Delivery Health Care™

Treatment with the LUTONIX® 035 DCB is contraindicated in patients with known hypersensitivity to paclitaxel or paclitaxel-related compounds, and in patients who cannot receive recommended antiplatelet and/or anticoagulant therapy.

[1] Based on animal studies conducted on the LUTONIX® 035 DCB Catheter, which may not be indicative of clinical performance.

Please consult product labels and instructions for use for indications, contraindications, hazards, warnings and precautions. ℞ Only